{"contentid": 488288, "importid": NaN, "name": "BeiGene gains NMPA approval for new biologics facility in Guangzhou", "introduction": "Sino-American biotech firm BeiGene today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.", "content": "<p>Sino-American biotech firm BeiGene (Nasdaq: BGNE) today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.</p>\n<p>At over one million square feet (100,000 square meters) and 8,000 liters of biologics capacity approved for commercial supply, this wholly-owned facility will immediately begin production of commercial supply of tislelizumab for the China market. An additional phase of construction currently in progress to bring total capacity to 64,000 liters is expected to be completed by the end of 2022.</p>\n<p>&ldquo;We started building this large-scale, commercial biologics manufacturing facility in 2017 to meet our expected future demand. Since that time, tislelizumab has been approved in several indications in China, included in the National Reimbursement Drug List (NRDL), and licensed to Novartis in Europe, North America, and Japan,&rdquo; commented Xiaobin Wu, president, chief operating officer and general manager of China at BeiGene.</p>\n<p>In January this year, Switzerland&rsquo;s Novartis (NOVN: VX) signed a strategic collaboration agreement to in-license tislelizumab for major markets outside China, in a deal that could be worth more than $2 billion to BeiGene.</p>\n<p>BeiGene&rsquo;s Guangzhou manufacturing facility has been designed to operate in compliance with current Good Manufacturing Practice (cGMP) standards adopted by the US Food and Drug Administration, the China NMPA and the European Medicines Agency.</p>\n<h2><strong>BeiGene launches Brukinsa in Canada</strong></h2>\n<p>BeiGene also today announced the official launch of Brukinsa (zanubrutinib) in Canada for the treatment of adult patients with Waldenstr&ouml;m&rsquo;s macroglobulinemia (WM). Brukinsa was authorized for sale by Health Canada in this indication on March 1, 2021, following the previous grant of priority review in September 2020.</p>\n<p>&ldquo;We are thrilled to officially launch Brukinsa in Canada, making this potentially best-in-class BTK inhibitor available to Canadian WM patients. Since the approval in Canada five weeks ago, our team has been working to set up distribution channels across the country for a speedy launch,&rdquo; said Peter Brenders, general manager of Canada at BeiGene. &ldquo;Together with the myBeiGene patient support program with comprehensive financial assistance, disease education, and emotional support, we are striving to ensure access for patients in Canada,&rdquo; he added.</p>", "date": "2021-04-08 13:58:00", "meta_title": "BeiGene gains NMPA approval for new biologics facility in Guangzhou", "meta_keywords": "BeiGene, Tilelizumab, Manufacturing plant, Approval, Novartis, Brukinsa, Launch, Waldenstr\u00c3\u00b6m\u00e2\u0080\u0099s", "meta_description": "BeiGene gains NMPA approval for new biologics facility in Guangzhou", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-08 13:57:18", "updated": "2021-04-08 14:09:09", "access": NaN, "url": "https://www.thepharmaletter.com/article/beigene-gains-nmpa-approval-for-new-biologics-facility-in-guangzhou", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "beigenebig.png", "image2id": "beigene-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Immuno-oncology, Rare diseases", "topic_tag": "Asia Pacific, Focus On, Product Launch, Production, Regulation", "geography_tag": "Canada, China", "company_tag": "BeiGene, Novartis", "drug_tag": "Brukinsa, tislelizumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-08 13:58:00"}